Evidence map›Paper›PMID 27384670›Full record

ArticleThe patient2017

What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.

Sophi Tatlock, Katja Rüdell, Charlotte Panter, Rob Arbuckle, Leslie R Harrold, William J Taylor, Tara Symonds

Open access · hybridAbstract readValidation Study
In one paragraph

Article in The patient, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Understanding data visualization techniques in qualitative studies used to develop and validate patient-reported outcome measures: a targeted literature review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Review
  5. Frontiers in pharmacology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Regulation of TRPV1 channel in monosodium urate-induced gouty arthritis in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  11. Article
  12. Article
  13. Better outcomes for patients with gout.Inflammopharmacology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sophi TatlockAdelphi Values, Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK. sophi.tatlock@adelphivalues.com.
Katja RüdellAstraZeneca, Da Vinci Building, Melbourn Science Park, Royston, Cambridgeshire, SG86EE, UK.
Charlotte PanterAdelphi Values, Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK.
Rob ArbuckleAdelphi Values, Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK.
Leslie R HarroldDepartment of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA.
William J TaylorRehabilitation Teaching and Research Unit, University of Otago Wellington, PO Box 7343, Wellington, New Zealand.
Tara SymondsClinical Outcomes Solutions Ltd, Shearway Road, Folkestone, CT194RH, UK.
Adelphi Group (United Kingdom) · GBAstraZeneca (United Kingdom) · GBUniversity of Massachusetts Chan Medical School · USUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesCharacterized by sudden onset of severe joint pain, swelling, redness, and tenderness to touch, gout 'flare ups' have a substantial impact on quality of life (QoL). This research employed a patient-centered approach to explore the symptoms and impacts of gout, and assess the content validity of existing patient-reported outcomes (PROs).

methodsQualitative interviews were conducted with 30 US gout patients (non-tophaceous: n = 20, tophaceous: n = 10) and five expert rheumatologists. Each interview included both concept elicitation (CE) questioning to learn about the patient experience and cognitive debriefing to assess the content validity of three PRO instruments (HAQ-DI, GAQ, and TIQ-20). Nine of the patients provided further real-time qualitative data through a smart phone application. All qualitative data were subject to thematic analysis using Atlas.ti. Two patient advisors and three expert clinicians were engaged as advisors at key stages throughout the research.

resultsInterview and real-time data identified the same core symptoms and proximal impact concepts. Severe pain (typically in joints of extremities) was described as the cardinal symptom, often accompanied by swelling, redness, heat, sensitivity to touch, and stiffness. Domains of QoL impacted included physical functioning, sleep, daily activities, and work. The PRO instruments were generally well-understood by patients, but each included items with questionable relevance to at least some of the sample, dependent on the specific joints affected.

conclusionsGout patients experience severe pain in affected joints, resulting in substantial limitations in physical functioning. Both the HAQ-DI and the TIQ-20 are useful for specific research purposes in the gout population, although modifications are recommended.

Indexed as

Patient Reported Outcome MeasuresAdultAgedAged, 80 and overFemaleGoutHumansMaleMiddle AgedQualitative ResearchQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesSymptom AssessmentTreatment OutcomeUnited States

Identifiers

PMID27384670
PMCPMC5250642
OpenAlexW2474492407

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.